ISCA2 and nonpapillary renal cell carcinoma: Thus, the discovery of these ISCA2 inhibitors with the capacity to induce ferroptosis in vivo through oral administration provides a breakthrough for the in vivo induction of ferroptosis for the treatment of ccRCC and other solid tumor types.